原始细胞CD33的表达水平对吉妥珠单抗奥唑米星治疗急性髓性白血病患者的疗效有积极影响。 - Suppr

The level of blast CD33 expression positively impacts the effect of gemtuzumab ozogamicin in patients with acute myeloid leukemia.

作者信息

Olombel Guillaume, Guerin Estelle, Guy Julien, Perrot Jean-Yves, Dumezy Florent, de Labarthe Adrienne, Bastie Jean-Noël, Legrand Ollivier, Raffoux Emmanuel, Plesa Adriana, Wagner-Ballon Orianne, Cornet Edouard, Salaun Véronique, Preudhomme Claude, Thomas Xavier, Pautas Cécile, Chantepie Sylvain, Turlure Pascal, Castaigne Sylvie, Dombret Hervé, Feuillard Jean

机构信息

Laboratoire d'Hématologie et Unité Mixte de Recherche 7276 Centre National de la Recherche Scientifique, Centre Hospitalier Universitaire (CHU) de Limoges, Faculté de Médecine, Université de Limoges et Centre National de la Recherche Scientifique, Limoges, France;

Service d'Hématologie Biologique, CHU, Dijon, France;

出版信息

Blood. 2016 Apr 28;127(17):2157-60. doi: 10.1182/blood-2016-01-689976. Epub 2016 Feb 29.

DOI:10.1182/blood-2016-01-689976

PMID:26929274

Abstract

摘要

相似文献

The level of blast CD33 expression positively impacts the effect of gemtuzumab ozogamicin in patients with acute myeloid leukemia.原始细胞CD33的表达水平对吉妥珠单抗奥唑米星治疗急性髓性白血病患者的疗效有积极影响。

Blood. 2016 Apr 28;127(17):2157-60. doi: 10.1182/blood-2016-01-689976. Epub 2016 Feb 29.

Gemtuzumab ozogamicin for acute myeloid leukemia.吉妥珠单抗奥佐米星治疗急性髓细胞白血病。

Blood. 2017 Nov 30;130(22):2373-2376. doi: 10.1182/blood-2017-09-797712. Epub 2017 Oct 11.

No evidence that CD33 splicing SNP impacts the response to GO in younger adults with AML treated on UK MRC/NCRI trials.没有证据表明，在英国医学研究理事会/英国国家癌症研究所试验中接受治疗的年轻急性髓系白血病成年人中，CD33剪接单核苷酸多态性会影响对吉妥单抗的反应。

Blood. 2018 Jan 25;131(4):468-471. doi: 10.1182/blood-2017-08-802157. Epub 2017 Dec 11.

Gemtuzumab ozogamicin for treatment of newly diagnosed CD33-positive acute myeloid leukemia.吉妥珠单抗奥佐米星治疗新诊断的 CD33 阳性急性髓系白血病。

Future Oncol. 2018 Dec;14(30):3199-3213. doi: 10.2217/fon-2018-0325. Epub 2018 Jul 24.

[Anti-CD33 monoclonal antibody drug conjugate--Gemtuzumab ozogamicin (GO)].[抗CD33单克隆抗体药物偶联物——吉妥珠单抗奥唑米星（GO）]

Nihon Rinsho. 2015 Feb;73 Suppl 2:215-8.

Gemtuzumab Ozogamicin Makes a Comeback.吉妥珠单抗奥佐米星卷土重来。

Cancer Discov. 2017 Nov;7(11):1208. doi: 10.1158/2159-8290.CD-NB2017-132. Epub 2017 Sep 20.

Expression of CD33 is a predictive factor for effect of gemtuzumab ozogamicin at different doses in adult acute myeloid leukaemia.CD33的表达是不同剂量吉妥珠单抗奥唑米星治疗成人急性髓系白血病疗效的预测因素。

Leukemia. 2017 May;31(5):1059-1068. doi: 10.1038/leu.2016.309. Epub 2016 Oct 31.

Coding polymorphisms in CD33 and response to gemtuzumab ozogamicin in pediatric patients with AML: a pilot study.CD33编码多态性与儿童急性髓系白血病患者对吉妥珠单抗奥唑米星的反应：一项初步研究

Leukemia. 2009 Feb;23(2):402-4. doi: 10.1038/leu.2008.185. Epub 2008 Jul 10.

Antibody-based therapy of acute myeloid leukemia with gemtuzumab ozogamicin.吉妥珠单抗奥佐米星治疗急性髓细胞白血病的抗体疗法。

Front Biosci (Landmark Ed). 2013 Jun 1;18(4):1311-34. doi: 10.2741/4181.

Gemtuzumab ozogamicin: an anti-CD33 immunoconjugate for the treatment of acute myeloid leukaemia.吉妥珠单抗奥唑米星：一种用于治疗急性髓系白血病的抗CD33免疫偶联物。

Expert Opin Biol Ther. 2008 Apr;8(4):527-40. doi: 10.1517/14712598.8.4.527.

引用本文的文献

Antibody-Drug Conjugates (ADCs): current and future biopharmaceuticals.抗体药物偶联物（ADCs）：当前及未来的生物制药

J Hematol Oncol. 2025 Apr 30;18(1):51. doi: 10.1186/s13045-025-01704-3.

Precision Medicine in Myeloid Neoplasia: Challenges and Opportunities.骨髓增殖性肿瘤中的精准医学：挑战与机遇

J Pers Med. 2025 Jan 26;15(2):49. doi: 10.3390/jpm15020049.

Overcoming the challenges of primary resistance and relapse after CAR-T cell therapy.克服 CAR-T 细胞治疗后原发性耐药和复发的挑战。

Expert Rev Clin Immunol. 2024 Jul;20(7):745-763. doi: 10.1080/1744666X.2024.2349738. Epub 2024 May 14.

Gemtuzumab Ozogamicin in Acute Myeloid Leukemia: Efficacy, Toxicity, and Resistance Mechanisms-A Systematic Review.吉妥单抗奥唑米星治疗急性髓系白血病：疗效、毒性及耐药机制——一项系统评价

Biomedicines. 2024 Jan 17;12(1):208. doi: 10.3390/biomedicines12010208.

Immunotherapy in hematologic malignancies: achievements, challenges and future prospects.血液系统恶性肿瘤的免疫治疗：成就、挑战与未来前景。

Signal Transduct Target Ther. 2023 Aug 18;8(1):306. doi: 10.1038/s41392-023-01521-5.

Treating CD33-Positive de novo Acute Myeloid Leukemia in Pediatric Patients: Focus on the Clinical Value of Gemtuzumab Ozogamicin.治疗儿童患者中CD33阳性初发急性髓系白血病：聚焦吉妥珠单抗奥唑米星的临床价值

Onco Targets Ther. 2023 Apr 29;16:297-308. doi: 10.2147/OTT.S263829. eCollection 2023.

The Use of Gemtuzumab Ozogamicin as Salvage Therapy in Patients with Acute Myeloid Leukemia: A Monocentric Real-World Experience.吉妥珠单抗奥佐米星在急性髓系白血病患者挽救治疗中的应用：一项单中心真实世界经验。

Medicina (Kaunas). 2023 Mar 2;59(3):498. doi: 10.3390/medicina59030498.

GSK3 inhibitor enhances gemtuzumab ozogamicin-induced apoptosis in primary human leukemia cells by overcoming multiple mechanisms of resistance.GSK3抑制剂通过克服多种耐药机制增强吉妥珠单抗奥唑米星诱导的原代人白血病细胞凋亡。

EJHaem. 2022 Dec 12;4(1):153-164. doi: 10.1002/jha2.600. eCollection 2023 Feb.

Role of Biomarkers in the Management of Acute Myeloid Leukemia.生物标志物在急性髓系白血病治疗中的作用。

Int J Mol Sci. 2022 Nov 22;23(23):14543. doi: 10.3390/ijms232314543.

Cellular and Molecular Biomarkers Predictive of Response to Immunotherapy in Acute Myeloid Leukemia.预测急性髓系白血病免疫治疗反应的细胞和分子生物标志物

Front Oncol. 2022 May 19;12:826768. doi: 10.3389/fonc.2022.826768. eCollection 2022.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

The level of blast CD33 expression positively impacts the effect of gemtuzumab ozogamicin in patients with acute myeloid leukemia.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献检索

文件翻译

深度研究

Suppr 超能文献

相似文献

引用本文的文献